Harmony Biosciences Holdings, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for HRMY, updated each market day.
HRMY AI Sentiment
AI sees no strong directional signal for Harmony Biosciences Holdings, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Harmony Biosciences Holdings, Inc. Common Stock
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Sector
Exchange
Market Cap
$1,687,413,063
Cap Tier
Employees
293
Headquarters
PLYMOUTH MEETING, PA
Listed Since
Aug. 19, 2020
HRMY Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
HRMY Volatility
Harmony Biosciences Holdings, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
